DSGN Stock Forecast: Design Therapeutics, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Design Therapeutics, Inc. hold a median 12-month price target of $21 — +132.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 53 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Design Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (81): The shares have been drifting up relative to others.
Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
DSGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on DSGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +132.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | RBC Capital | Maintains | Outperform | $20 → $19 |
| 2 Oct 2026 | Wells Fargo | Initiates | Overweight | $26 |
| 4 May 2026 | Oppenheimer | Maintains | Outperform | $18 → $21 |
| 16 Mar 2026 | Jefferies | Initiates | Buy | — |
| 10 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 7 Jan 2026 | Oppenheimer | Initiates | Outperform | — |
| 3 Dec 2025 | Leerink Partners | Upgrade | Outperform | — |
| 20 Nov 2025 | RBC Capital | Upgrade | Outperform | — |
| 6 Nov 2025 | RBC Capital | Maintains | Sector Perform | — |
| 6 Aug 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 7 May 2024 | Piper Sandler | Upgrade | Overweight | — |
| 20 Mar 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 20 Mar 2024 | Wedbush | Reiterates | Neutral | — |
| 14 Nov 2023 | RBC Capital | Maintains | Sector Perform | — |
| 15 Aug 2023 | RBC Capital | Downgrade | Sector Perform | — |
| 15 Aug 2023 | SVB Leerink | Downgrade | Market Perform | — |
| 15 Aug 2023 | Wedbush | Downgrade | Neutral | — |
| 10 May 2023 | RBC Capital | Maintains | Outperform | — |
| 10 May 2023 | Wedbush | Maintains | Outperform | — |
| 4 May 2023 | Goldman Sachs | Upgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for DSGN.
This page is one stock. Monday covers all of them.
DSGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
DSGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Design Therapeutics, Inc. returned +14.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
DSGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.8×
- EV / EBITDA
- —
Cheaper than 32% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −36.9%
- Return on assets
- −23.9%
- Dividend yield
- —
Higher than 25% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Design Therapeutics, Inc. has a market value of $577.6M and an enterprise value of $371.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$70.8M.
Diluted earnings per share, trailing twelve months: −$1.18.
Free cash flow in the twelve months to 30 June 2026: −$55.1M.
Design Therapeutics, Inc. employs 60 people.
Data provided by Twelve Data
DSGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at DSGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Design Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about DSGN
What is the DSGN stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Design Therapeutics, Inc. have a median 12-month price target of $21, with estimates ranging from $19 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is DSGN stock a buy right now?
Of the 8 analysts covering Design Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Design Therapeutics, Inc. 53 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank DSGN?
As at 21 Nov 2026, Design Therapeutics, Inc. ranks 53 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).
Will DSGN stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +132.8% from the last close, and Ticker Nerd's factor model ranks Design Therapeutics, Inc. 53 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the DSGN stock forecast for 2030?
No analyst covering Design Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DSGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $26 over the next 12 months.
How has DSGN stock performed over the past year?
Design Therapeutics, Inc. returned +14.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Design Therapeutics, Inc. do?
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease.
About Design Therapeutics, Inc.
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing GeneTAC small-molecule therapies for serious genetic diseases. The company’s current programs target inherited disorders driven by nucleotide repeat expansion mutations, with a portfolio that includes treatments in development for Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy type-1, and Huntington’s disease. Its approach centers on designing therapeutic candidates that act on the underlying genetic cause of disease rather than only addressing symptoms. Design Therapeutics serves the biotechnology and drug-development market through its proprietary platform, which supports research, preclinical work, and clinical development of novel medicines for patients with high unmet medical needs. The company is headquartered in Carlsbad, California.
CEO Mr. Pratik Shah Ph.D. · 60 employees · United States · https://www.designtx.com